TrialInternational journal of hematology2025

A Phase 1/2 study of teclistamab, a humanized BCMA × CD3 bispecific Ab in Japanese patients with relapsed/refractory MM.

Tadao Ishida et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.